Table 2

The immunoprophylaxis outcomes for newborns and infants
Study Newborns number HBsAgseropositivity n (%) HBV DNA seropositivity n (%)
Telbivudine/Control Telbivudine/ Control Telbivudine Control
n At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mp 12 mo
Zhang 2009 [21] 31/30 2 (6.5%) NA 0 (0%) NA 5 (16.7%) NA 4 (13.3%) NA NA NA NA NA NA NA NA NA
Zhao 2010 [22] 30/30 NA NA NA 1 (3.3%) NA NA NA 3 (10.0%) NA NA NA 1 (3.3%) NA NA NA 8 (26.7%)
Zeng 2010 [20] 22/26 2 (9.1%) NA NA NA 9 (34.6%) NA NA NA 0 (0%) NA NA NA 4 (15.4%) NA NA NA
Zhang 2010 [21] 60/60 6 (10.0%) NA NA 1 (1.7%) 18 (30.0%) NA NA 11 (18.3%) 5 (18.3%) NA NA 1 (1.7%) 18 (30.0%) NA NA 11 (18.3%)
Yao 2011 [23] 28/30 1 (3.6%) 0 (0%) NA NA 5 (16.7%) 4 (13.3%) NA NA NA NA NA NA NA NA NA NA
Han 2011 [5] 136/94 13 (9.6%) NA 0 (0%) NA 28 (29.8%) NA 7 (8.0%) NA 0 (0%) NA 0 (0%) NA 9 (9.6%) NA 7 (8.0%) NA

HBsAg: hepatitis B surface antigen; NA: not available.

Deng et al.

Deng et al. Virology Journal 2012 9:185   doi:10.1186/1743-422X-9-185

Open Data